Abstract: Stable solutions of lipophilic drugs, such as cyclosporin, forming a polar lipid self-emulsifying drug delivery system. The solutions can include lipophilic drugs, such as cyclosporin, dissolved in a polar lipid, such as having a C6-C12 fatty acid monoglyceride content of at least about 50%, surfactants and triglycerides. The composition forms a fine emulsion on exposure to water. The encapsulated dosage form of this composition needs neither a hydrophilic component nor air-tight blister packaging, and is particularly suitable for oral administration.
Type:
Application
Filed:
April 7, 2006
Publication date:
August 24, 2006
Applicant:
Pliva, Inc. (formerly known as Sidmak Laboratories, Inc.)
Abstract: An extended release tablet comprising a core including albuterol sulfate and extended release agent; and an extended release coating on the core to provide for sustained release of the albuterol sulfate.
Type:
Application
Filed:
April 12, 2002
Publication date:
October 23, 2003
Applicant:
SIDMAK LABORATORIES, INC.
Inventors:
Davejibhai Kumbhani, Harish B. Pandya, Hiren Patel
Abstract: The invention comprises a stable solution of cyclosporine forming a polar lipid self-emulsifying drug delivery system ("PLSEDDS"). The composition typically consists of cyclosporine dissolved in a polar lipid, such as a medium chain monoglyceride of C.sub.6 -C.sub.12 fatty acids having a monoglyceride content of at least 50% and a surfactant. The composition provided here instantly forms a fine emulsion on exposure to water. The encapsulated dosage form of this composition needs neither a hydrophilic component nor air-tight blister packaging, and is particularly suitable for oral administration.
Type:
Grant
Filed:
January 22, 1997
Date of Patent:
January 12, 1999
Assignee:
Sidmak Laboratories, Inc.
Inventors:
Vinayak T. Bhalani, Satishchandra P. Patel
Abstract: A sustained release tablet adapted to provide an initial immediate release of an active agent, a period of no release of the active agent, followed by a substantially constant, rate of release of the active agent. The tablet includes (a) a compressed tablet core containing an active agent, an insoluble binder and an insoluble; (b) a barrier coating formed over the tablet core, the barrier coating including a mixture of soluble and insoluble polymers and a plasticizer; (c) an active coating deposited over the barrier coating, the active coating including an active agent, a soluble polymer and a plasticizer; and (d) a film coating formed over the active coating, the film coating containing a soluble polymer and plasticizer.
Type:
Grant
Filed:
January 29, 1992
Date of Patent:
April 18, 1995
Assignee:
Sidmak Laboratories, Inc.
Inventors:
Satischandra P. Patel, Vinayak T. Bhalani
Abstract: A stable, solid choline magnesium salicylte inclusion complex composition which comprises choline salicylate, magnesium salicylate and magnesium aluminum silicate, and granulation method for preparing the solid inclusion complex composition utilizing liquid salicylate is provided. The invention is also directed to methods of administering the compoitions of the invention to treat osteoarthritis, rheumatoid arthritis, and acute painful shoulder.
Type:
Grant
Filed:
April 26, 1990
Date of Patent:
August 27, 1991
Assignee:
Sidmak Laboratories, Inc.
Inventors:
Satishchandra P. Patel, Vinayak T. Bhalani